Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $26.67

Pacira BioSciences, Inc. (NASDAQ:PCRX) has earned a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $26.67.

A number of research analysts have recently issued reports on the company. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and raised their price objective for the company from $8.00 to $25.00 in a research note on Thursday, January 30th. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price target on shares of Pacira BioSciences in a research note on Tuesday, April 8th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. HC Wainwright upped their price target on shares of Pacira BioSciences from $48.00 to $65.00 and gave the company a “buy” rating in a report on Tuesday, April 8th. Finally, Barclays raised their price target on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a report on Friday, February 28th.

Hedge Funds Weigh In On Pacira BioSciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Hennion & Walsh Asset Management Inc. raised its position in shares of Pacira BioSciences by 18.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 56,385 shares of the company’s stock worth $1,062,000 after acquiring an additional 8,636 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after buying an additional 2,749 shares in the last quarter. Gagnon Securities LLC grew its position in shares of Pacira BioSciences by 4.8% in the 4th quarter. Gagnon Securities LLC now owns 321,743 shares of the company’s stock worth $6,062,000 after buying an additional 14,800 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in shares of Pacira BioSciences by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock worth $184,000 after acquiring an additional 918 shares in the last quarter. Finally, Caitlin John LLC lifted its position in Pacira BioSciences by 1,850.0% during the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares during the period. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

PCRX stock opened at $25.81 on Tuesday. The firm has a market cap of $1.19 billion, a P/E ratio of -12.71 and a beta of 0.56. The firm’s fifty day moving average is $24.65 and its 200 day moving average is $21.95. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $31.67. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.